↓ Skip to main content

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

Overview of attention for article published in Neurology, April 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Readers on

mendeley
243 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
Published in
Neurology, April 2012
DOI 10.1212/wnl.0b013e3182516244
Pubmed ID
Authors

I.H. Richard, M.P. McDermott, R. Kurlan, J.M. Lyness, P.G. Como, N. Pearson, S.A. Factor, J. Juncos, C. Serrano Ramos, M. Brodsky, C. Manning, L. Marsh, L. Shulman, H.H. Fernandez, K.J. Black, M. Panisset, C.W. Christine, W. Jiang, C. Singer, S. Horn, R. Pfeiffer, D. Rottenberg, J. Slevin, L. Elmer, D. Press, H.C. Hyson, W. McDonald, Irene Richard, William McDonald, Michael McDermott, Peter G. Como, Roger Kurlan, Jeffrey M. Lyness, Nancy Pearson, Barbara Sommerfeld, Cheryl Deeley, Tania de la Torre, Michele Barnard, April Wilson, Maryann Lincoln, Paula Damgaard, Melissa Gerstenhaber, Kelly Dustin, Nancy Zappala, Camille Swartz, Mary Creech, Elda Shipley, Samantha Blankenship, Monica Beland, Jessie Roth, Heather Burnette, Tamara Foxworth, Monica Quesada, Mary Lloyd, Brenda Pfeiffer, Joy Hansen, Joy Folie, Renee Wagner, Julia Spears, Colleen Taylor, Rachel Brown, Lisa Iguchi, Chen Lim, Kori LaDonna, Julie Megens, Matthew Menza, Jeffrey Cummings, Robert Hamer, Kathleen Shannon, Joanne Odenkirchen, Robin Conwit, Christopher Beck, Donna LaDonna, Jan Bausch, Scott Kim, Ron Chismar, Sinead Quinn, Steve Bean, Susan Daigneault, Patricia Lindsay, Tori Ross, Katie Kompoliti

Abstract

To evaluate the efficacy and safety of a selective serotonin reuptake inhibitor (SSRI) and a serotonin and norepinephrine reuptake inhibitor (SNRI) in the treatment of depression in Parkinson disease (PD).

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 243 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United States 2 <1%
United Kingdom 2 <1%
Switzerland 2 <1%
Canada 2 <1%
Unknown 235 97%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 34 14%
Student > Master 31 13%
Student > Ph. D. Student 23 9%
Other 19 8%
Student > Bachelor 19 8%
Other 56 23%
Unknown 61 25%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 80 33%
Neuroscience 28 12%
Psychology 14 6%
Agricultural and Biological Sciences 11 5%
Nursing and Health Professions 10 4%
Other 30 12%
Unknown 70 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 42. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2025.
All research outputs
#1,223,248
of 33,779,198 outputs
Outputs from Neurology
#2,047
of 25,922 outputs
Outputs of similar age
#5,496
of 207,141 outputs
Outputs of similar age from Neurology
#12
of 302 outputs
Altmetric has tracked 33,779,198 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 25,922 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.8. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 207,141 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 302 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.